Abstract
Leukocytes contribute to the pathogenesis of thrombosis in essential thrombocythemia (ET) through recently discovered mechanisms of activation and interaction with platelets and endothelial cells.
To evaluate whether an increased leukocyte count was associated with thrombosis and whether this effect can be modulated by therapy, we analyzed the clinical course of 439 patients with ET followed at our Institution. The strength of the association was measured at diagnosis or before thrombotic events by multivariable analyses carried out using data at baseline as well as timevarying covariates. The results showed that: a) increased leukocyte count at diagnosis was associated with thrombosis during follow-up ("baseline analysis", RR 2.3, 95% CI 1.4-3.9, p=0.001); b) Hydroxyurea lowered leukocytosis and reduced the strength of the association between leukocytosis and thrombosis ("time-dependent analysis", RR 1.6, 95% CI 0.9-2.0, n.s.), c) the association of leukocytosis and thrombosis was more evident in untreated low-risk patients (RR 2.7, 95% CI 1.2-6.4, p=0.01) as compared to HU-treated high-risk patients (RR 1.6, 95% CI 0.8-3.2, n.s.); d) the presence of Jak2 V617F was not identified as a risk factor for thrombosis during follow-up despite a significant association between the mutation and leukocytosis. We suggest to validate these findings in prospective clinical studies.
Introduction
Essential Thrombocythemia (ET) is a Philadelphia negative myeloproliferative disorder (MPD), distinct from polycythemia vera and idiopathic myelofibrosis and characterized by persistent thrombocytosis, excessive proliferation of megakaryocytes in the bone marrow, normal erythrocytic mass and the absence of prominent bone marrow fibrosis. 1 In spite of the insidious clinical onset, ET may be complicated by severe vascular complications and presents a variable potential to undergo progression to myelofibrosis or transformation into acute leukemia. The aim of cytoreductive therapy is to prevent thrombosis and hemorrhage without increasing the risk of hematological transformation. To accomplish this goal, drugs are prescribed after a stratification approach dictated by the thrombotic risk. 2 In a previous paper we showed that age over 60 years and prior thrombotic events were the two independent factors able to predict the occurrence of vascular complications in ET patients. 3 This stratification is now widely accepted for treatment decisions in the single patient and in clinical trials. 4, 5 In the last few years, new information on the pathogenesis of thrombosis in MPD became available, including the role of leukocyte activation and interaction with platelets and endothelial cells [6] [7] [8] [9] and a possible place of the recently identified JAK2 V617F mutation, found in nearly 50%
of ET patients. 10 Therefore, by using our own database, we analyzed the prognostic role for thrombosis of other potential determinants of the individual risk such as white blood cells values and JAK2 mutational status in a large population of ET patients.
Patients and methods

Patients
All the analyses were performed using the database of 439 patients with ET regularly followed at our Hematology Division from 1981 to 2006 (Table 1) . ET was diagnosed according to PVSG criteria. 11 One hundred eighty-nine patients (43%) were newly diagnosed whereas the others were referred to our Division after being diagnosed with ET elsewhere. Only patients with confirmed diagnosis were included in the follow-up. The time elapsed from diagnosis to referral is reported in Table 1 . Data regarding laboratory values, treatments and clinical outcomes were collected at diagnosis and at least every 6 months during the follow-up in all patients. Jak2 mutation was assessed in 277 cases (63%). Informed consent was obtained for each subject.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From Patients were classified as being at low-and high-risk for thrombosis according to standard risk factors (age ≥ 60 years and/or a previous major thrombotic event). Low risk patients were followed with no cytoreductive therapy whereas high-risk patients were given hydroxyurea (HU) with the aim to reduce platelets <600 x10 9 /L. 4 HU was also given to 10 (2%) patients at low thrombotic risk but with extreme thrombocytosis (platelet count > 1,500x10 9 For personal use only. on July 15, 2017. by guest www.bloodjournal.org From enzyme for 4 h at 37°C. Mutant homozygous allele was not digested; mutant heterozygous allele was partially digested while wild type allele was completely digested into 241bp, 189bp and 30pb products. 12 
Statistical methods
Univariate analysis was performed to evaluate differences in proportions by the chi-square and Fisher's exact tests. Differences in continuous variables were tested using the t-test.
Two different multivariable approaches have been adopted by fitting various Cox proportional-hazards models.
Firstly, a multivariable analysis using values measured at diagnosis was used to assess whether the level of exposition for a potential risk predictor captured at diagnosis could be found to be a statistically significant marker of increased probability of recurrence of thrombosis during follow-up. The multivariable model to assess this hypothesis has been fitted after adjusting for gender, standard risk factors for thrombosis (age ≥ 60 years and/or previous thrombosis), and for median levels of white blood cell count, hemoglobin, hematocrit and platelets registered at diagnosis.
Secondly, the database was explored using Cox proportional-hazards model with timevarying covariates to evaluate risk, and with right censoring at the first thrombotic event or last date of follow-up. This analysis included variables considered "fixed" in time (i.e., gender and standard risk factors, defined as above) and time-varying variables: treatments (HU, anti platelet drugs) and count of blood cells (median levels of hemoglobin, hematocrit, white blood cells, platelets).
Continuous variables have been analyzed using median levels at baseline as cut-off values and maintaining the same cut-off values in the time-dependent analysis for consistency. Time-dependent variables were updated yearly, and the last available value before a thrombotic event was used to estimate the relative risk. Where appropriate, the substitution of the missing data for incomplete repeated measures was done with the last value carried forward. The latter analysis allowed assessing whether the level of exposition to a factor measured before a thrombotic recurrence was associated with the probability of having that event .
Analyses were performed with SAS 9.1 software. All probability values are two tailed (<0.05).
For
Results
The characteristics of the 439 patients are shown in Table 1 . One-hundred-twenty-nine episodes of vascular thrombosis were registered at diagnosis or in the previous history in 113 patients (26%).
During the follow-up, seventy-eight events were diagnosed in 67 patients (15%). The distribution of events is quoted in Table 1 .
On univariate analysis, parameters at diagnosis associated with thrombosis registered in the follow-up were age ≥ 60 years and previous history of thrombosis (p=0.02) and leukocytes count above the median level of 8.7 x10 9 /L (p=0.01). No significant association was found considering arterial and venous thrombosis separately, gender, median levels of hemoglobin, hematocrit and platelets.
Two statistical multivariable analyses were performed considering the variables at diagnosis and before the vascular events occurring during follow-up ( Table 2 ).
The multivariable "baseline" analysis taking into account gender, standard risk factors for thrombosis (age ≥ 60 years and/or previous thrombosis), median levels of hemoglobin, hematocrit, platelets and white blood cells showed a significant and independent association between standard risk factors as well as high levels of white blood cells with the occurrence of thrombosis in the follow-up (hazard ratio 2.3 for both). Platelet count above the median level of 784 x10 9 /L was not found independent risk factors for subsequent vascular events.
On multivariable "time-dependent" analysis we took into account the last value of blood cell counts measured before vascular events. Treatment with HU decreased the leukocytes count of about 30%, from the baseline median level of 8.7 x10 9 /L to 6.1 x10 9 /L, and their statistical significance was lost (hazard ratio 1.6, 95% confidence interval 0.9 to 2.8, p=0.06). In contrast, conventional risk factors (age ≥ 60 years and/or previous thrombosis) retained their independent significant value (hazard ratio 1.8, 95% confidence interval 1.1 to 3.0, p=0.04). The antithrombotic efficacy of treatment was confirmed by the demonstration of an independent protective effect of both HU and low-dose aspirin (hazard ratio 0.5 for both).
In order to evaluate the interaction between conventional risk categories and WBC levels, univariate analysis showed a different risk profile of white blood cell levels in low-risk and highrisk patients. The rate of thrombotic events was significantly higher in low-risk patients with high leukocytes as compared to low-risk patients with low leukocyte count (relative risk 2.7, 95 percent confidence interval 1.2 to 6.4). In contrast, leukocyte levels did not significantly predict the risk of thrombosis among high-risk ET patients (relative risk 1.6, 95 percent confidence interval 0.8 to
3.2). In multivariable time-dependent model (Table 3), low-risk patients with high levels of
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From leukocytes were associated with a significantly increased risk of thrombosis (hazard ratio 3.1, 95 percent confidence interval 1.4 to 7.1), similar to that observed in high-risk patients with normal level of leukocytes (hazard ratio 2.5, 95 percent confidence interval 1.0 to 6.0). The presence of both the risk factors was associated with the highest probability to develop a vascular event during the follow-up (hazard ratio 5, 95 percent confidence interval 2.1 to 11.9).
As far as the Jak2 mutation is concerned, in univariate analysis performed on 277 patients (38 vascular events valuable in the follow-up), leukocytes were found to be significantly higher in patients with the V167F mutation (90 of 151, 60%) than in Jak2 wild type patients (45 of 126, 36%), (p<0.0001). Moreover, V617F mutation status was associated with higher hemoglobin levels and lower platelet counts (p<0.0001 for both). In multivariable analysis, Jak2 mutation was not found to be a significant independent predictor of thrombosis occurring in the course of the disease (hazard ratio 1.4, 95 percent confidence interval 0.7 to 3.0). 
Discussion
This study shows that an increased number of WBC is a relevant marker of thrombosis in patients with ET and that this risk factor is reduced by cytoreductive treatment with HU. Several pieces of evidence support these statements.
Firstly, a multivariable analysis demonstrates that patients with baseline WBC count above the median had an hazard risk of developing thrombosis about twice the patients with lower WBC counts. This finding is in keeping with a recent analysis by Wolansky et al. 13 who reported that age, previous thrombosis and leukocytosis were independent risk factors for both major thrombosis and a poorer long-term survival when evaluated at diagnosis. Unlike our results, these investigators found that previous history of arterial but not venous thrombosis was associated with recurrence of thrombotic events.
Secondly, cytoreductive therapy lowered the number of WBC during the follow-up and this was associated with a reduction of their thrombogenic effect.
Thirdly, the role of WBC in predicting thrombosis appears to be more evident in untreated low-risk than in treated high-risk patients.
Several pathophysiological mechanisms may explain a thrombogenic role of WBC in MPDs. Our group and others showed that in these disorders neutrophils circulate in an activated state and are able to bind to platelets in a dynamic adhesive process, which reflects the activation of both platelets and leukocytes. [6] [7] [8] [9] Thus, process triggers the expression of tissue factors as well as endothelial activation and damage. 14 In addition, leukocytosis may contribute to inflammatory processes in atherosclerotic plaques and in this way increase the probability of vascular events 15, 16, 17 . Interestingly, leukocytes are of major importance in the patophysiology of other occlusive diseases, such as sickle-cell disease. 18 In these patients, an increased baseline white cell count has been found to be an independent risk factor for acute chest syndrome and cerebral infarction, and quantitative and qualitative reductions in leukocytes during Hydroxyurea treatment were correlated with a better disease outcome.
In all our analyses, platelet number did not show any correlation with the vascular events.
While extreme thrombocytosis may correlate with the occurrence of hemorrhage due to an acquired vonWillebrand disease, 19, 20, 21 the contribution of platelet number to major thrombotic events remains poorly established. 22 In a randomized clinical trial that included high risk ET patients, HU treatment was found to be superior to Anagrelide, a selective cytoreductive antiplatelet drug, in preventing arterial thrombosis. 5 This supports the concept that the reduction of events, achieved by
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The putative thrombogenic role of leukocytosis generates the hypothesis of a reassessment of the risk stratification of ET patients. Our data suggest that "true" low-risk patients, not requiring cytoreductive therapy, are those without conventional clinical risk factors (age < 60 years and no previous thrombosis) and low WBC count. In fact, patients previously classified as "low-risk" but carrying leukocytosis present a thrombotic risk similar to the conventional "high-risk" patients.
These patients should be strongly considered for a cytoreductive therapy, if our retrospective data will be confirmed in other prospective clinical studies.
The contribution of Jak2 mutation in the risk classification of ET patients is still a matter of debate. Some Authors have reported an association between Jak2 V617F, thrombosis, 23, 24 but this was not confirmed in other studies. 25, 26 Different patients selections, and study designs may have played a role in these discrepancies. In our analysis, leukocytosis was more frequent in patients carrying the Jak2 mutation but a significant role of Jak2 in predicting thrombosis was not found. It should be noted, however, that the JAK2 mutation was evaluated in only 277 of the 439 cases included in the study (with only 38 vascular events valuable) and this can have reduced the statistical power of the analysis. Interestingly, Jak2 mutated ET patients were found to have a more pronounced activation of platelets and leukocytes 9, 27 and a more effective response to HU treatment 23 than those without the mutation. The findings in the current study suggest that previous reports of an association between thrombosis and the presence of Jak2 V617F in ET might have been an indirect effect from leukocytosis, which is significantly associated with the presence of the mutation.
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